An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions

NCT05839951 · clinicaltrials.gov ↗

COMPLETED

Status

818

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer (mCRC)

Interventions

DRUG: Regorafenib (BAY73-4506, Stivarga®)
DRUG: TAS-102 (trifluridine and tipiracil, Lonsurf®)
DRUG: Bevacizumab

Sponsor

Bayer